`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`ELI LILLY AND COMPANY
`Petitioner
`v.
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner
`______________________
`
`IPR2018-01426
`Patent No. 9,890,211
`______________________
`
`PETITIONER’S EXHIBIT LIST AS OF AUGUST 8, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`Exhibit 1001 U.S. Patent No. 9,890,211
`
`Description
`
`Exhibit 1002 Reserved
`
`Exhibit 1003 Reserved
`
`Exhibit 1004 Reserved
`
`Exhibit 1005 Reserved
`
`Exhibit 1006 Reserved
`
`Exhibit 1007 Reserved
`
`Exhibit 1008 Reserved
`
`Exhibit 1009 Reserved
`
`Exhibit 1010 Reserved
`
`Exhibit 1011 Reserved
`
`Exhibit 1012 Declaration of Andrew Charles, M.D. (U.S. Patent No. 9,890,211)
`
`Exhibit 1013 Declaration of Alain P. Vasserot (U.S. Patent No. 9,890,211)
`
`Exhibit 1014 Reserved
`
`Exhibit 1015 Reserved
`
`Exhibit 1016 Reserved
`
`Exhibit 1017 Reserved
`
`Exhibit 1018 Reserved
`
`Exhibit 1019 Teva’s U.S. Provisional Application No. 60/736,623
`
`Exhibit 1020 Teva’s PCT Application No. WO 2007/054809
`
`1
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1021 Tan et al., “Demonstration of the Neurotransmitter Role of
`Calcitonin Gene-Related Peptides (CGRP) by Immunoblockade
`with Anti-CGRP Monoclonal Antibodies,” Br. J. Pharmacol.
`(1994) 111: 703-710
`
`Exhibit 1022 Tan et al., “Calcitonin Gene-Related Peptide as an Endogenous
`Vasodilator: Immunoblockade Studies in vivo with an Anti-
`Calcitonin Gene-Related Peptide Monoclonal Antibody and Its
`Fab’ Fragment,” Clinical Sci. (1995) 89: 565-573
`
`Exhibit 1023 Queen et al., U.S. Patent No. 6,180,370
`
`Exhibit 1024 Doods et al., “Pharmacological Profile of BIBN4096BS, the First
`Selective Small Molecule CGRP Antagonist,” Br. J. Pharmacol.
`(2000) 129: 420-423
`
`Exhibit 1025 Olesen et al., “Calcitonin Gene-Related Peptide Receptor
`Antagonist BIBN 4096 BS for the Acute Treatment of Migraine,”
`N. Engl. J. Med. (2004) 350: 1104-1110
`
`Exhibit 1026 Sveinsson, International Publication No. WO 2004/014351
`
`Exhibit 1027 Salmon et al., U.S. Patent Application Publication No. US
`2002/0162125
`
`Exhibit 1028 De Lacharriere et al., U.S. Patent No. 6,344,438
`
`Exhibit 1029 Olesen et al., “S26 CGRP Antagonism as a New Therapeutic
`Principle in Acute Migraine,” Neuropeptides (2004) 38: 110-131
`
`Exhibit 1030 Arndt et al., “CGRP Antagonism — A Valid New Concept for the
`Treatment of Migraine Pain,” Neuropeptides (2004) 38: 110-131
`
`Exhibit 1031 Arulmani et al., “Calcitonin Gene-related Peptide and Its Role in
`Migraine Pathophysiology,” Eur. J. Pharmacol. (2004) 143: 315-
`330
`
`2
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1032 Frobert et al., “A Sensitive Sandwich Enzyme Immunoassay for
`Calcitonin Gene-Related Peptide (CGRP): Characterization and
`Application,” Peptides (1999) 20: 275-284
`
`Exhibit 1033 Wong et al., “Monoclonal Antibody to Rat α-CGRP: Production,
`Characterization, and in vivo Immunoneutralization Activity,”
`Hybridoma (1993) 12: 93-106
`
`Exhibit 1034 Rist et al., “From Micromolar to Nanomolar Affinity: A Systematic
`Approach to Identify the Binding Site of CGRP at the Human
`Calcitonin Gene-Related Peptide 1 Receptor,” J. Med. Chem.
`(1998) 41: 117-123
`
`Exhibit 1035 Edvinsson and Hargreaves, The Headaches 289-299 (3rd ed. 2006)
`
`Exhibit 1036 Reserved
`
`Exhibit 1037 Reserved
`
`Exhibit 1038 Mason et al., “Release of the Predicted Calcitonin Gene-Related
`Peptide from Cultured Rat Trigeminal Ganglion Cells,” Nature
`(1984) 308: 653-655
`
`Exhibit 1039 Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Exhibit 1040 Arulmozhi et al., “Migraine: Current Concepts and Emerging
`Therapies,” Vascular Pharmacol. (2005) 43: 176-187
`
`Exhibit 1041 Durham, “CGRP-Receptor Antagonists - A Fresh Approach to
`Migraine Therapy?” N. Engl. Med. (2004) 250(11): 1073-1075
`
`Exhibit 1042
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of BIBN
`4096 BS, the First Selective Small Molecule Calcitonin Gene-
`related Peptide Receptor Antagonist, Following Single Intravenous
`Administration in Healthy Volunteers,” Cephalalgia (2004) 24:
`645-656
`
`3
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1043 Goadsby et al., “Vasoactive Peptide Release in the Extracerebral
`Circulation of Humans During Migraine Headache,” Annals of
`Neurology (1990) 28(2): 183-187
`
`Exhibit 1044 Goadsby and Edvinsson, “The Trigeminovascular System and
`Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals of
`Neurology (1993) 33(1): 48-56
`
`Exhibit 1045 Juhasz et al., “NO-induced Migraine Attack: Strong Increase in
`Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration
`and Negative Correlation with Platelet Serotonin Release,” Pain
`(2003) 106: 461-470
`
`Exhibit 1046 Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache: Neuropeptide
`Changes and Effects of Acute Attacks Therapies,” Brain (1994)
`117: 427-434
`
`Exhibit 1047 Lassen et al., “CGRP May Play a Causative Role in Migraine,”
`Cephalagia (2002) 22: 54-61
`
`Exhibit 1048 Louis et al., “Antibodies to Calcitonin-Gene Related Peptide
`Reduce Inflammation Induced by Topical Mustard Oil But Not that
`Due to Carrageenin in the Rat,” Neuroscience Letters (1989) 102:
`257-260
`
`Exhibit 1049 Dockray et al., “Immunoneutralization Studies with Calcitonin
`Gene-Related Peptide,” Annals of N.Y. Acad. Scis. (1992) 258-267
`
`Exhibit 1050 Louis et al., “The Role of Substance P and Calcitonin Gene-Related
`Peptide in Neurogenic Plasma Extravasation and Vasodilation in
`the Rat,” Neuroscience (1989) 32(3): 581-586
`
`Exhibit 1051 Sigma-Aldrich, Biochemicals & Reagents for Life Science
`Research 350-352 (2004)
`
`4
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1052 Escott and Brain, “Effect of a Calcitonin Gene-Related Peptide
`Antagonist (CGRP8-37) on Skin Vasodilatation and Oedema
`Induced by Stimulation of the Rat Saphenous Nerve,” Br. J.
`Pharmacol. (1993) 110: 772-776
`
`Exhibit 1053 Reserved
`
`Exhibit 1054 Reserved
`
`Exhibit 1055 Andrew et al., “Monoclonal Antibodies Distinguishing α and β
`Forms of Calcitonin Gene-Related Peptide,” J. Immunol. Methods
`(1990) 154: 87-94
`
`Exhibit 1056 Reichert et al., “Monoclonal Antibody Successes in the Clinic,”
`Nature Biotechnol. (2005) 23: 1073-1078
`
`Exhibit 1057 Projan et al., “Small Molecules for Small Minds? The Case for
`Biologic Pharmaceuticals,” Expert Opin. Biol. Ther. (2004) 4:
`1345-1350
`
`Exhibit 1058 Janeway et al., Immunobiology 93-122 (5th ed. 2001)
`
`Exhibit 1059 Janeway et al., Immunobiology 123-154 (5th ed. 2001)
`
`Exhibit 1060 Janeway et al., Immunobiology 341-380 (5th ed. 2001)
`
`Exhibit 1061 Van Valen et al., “Calcitonin Gene-Related Peptide (CGRP)
`Receptors are Linked to Cyclic Adenosine Monophosphate
`Production in SK-N-MC Human Neuroblastoma Cells,”
`Neuroscience Letters (1990) 119: 195-198
`
`Exhibit 1062 Kipriyanov and Le Gall, “Generation and Production of Engineered
`Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Exhibit 1063 Elgert, Immunology: Understanding the Immune System 58-78 (1st
`ed. 1996)
`
`5
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1064 Wright and Morrison, “Effect of Glycosylation on Antibody
`Function: Implications for Genetic Engineering,” Trends
`Biotechnol. (1997) 15: 26-32
`
`Exhibit 1065 Brüggemann et al., “Comparison of the Effector Functions of
`Human Immunoglobulins Using a Matched Set of Chimeric
`Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Exhibit 1066 Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-736
`
`Exhibit 1067 Tao and Morrison, “Studies of Aglycosylated Chimeric Mouse-
`Human IgG: Role of Carbohydrate in the Structure and Effector
`Functions Mediated by the Human IgG Constant Region,” J.
`Immunol. (1989) 143: 2595-2601
`
`Exhibit 1068 Maynard and Georgiou, “Antibody Engineering,” Annu. Rev.
`Biomed. Eng. (2000) 2: 339-376
`
`Exhibit 1069 Chester and Hawkins, “Clinical Issues in Antibody Design,”
`Trends Biotechnol. (1995) 13: 294-300
`
`Exhibit 1070 Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Exhibit 1071 Gavilondo and Larrick, “Antibody Engineering at the Millennium,”
`BioTechniques (2000) 29: 128-145
`
`Exhibit 1072 Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Exhibit 1073 Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Exhibit 1074 Kettleborough et al., “Humanization of a Mouse Monoclonal
`Antibody by CDR-Grafting: The Importance of Framework
`Residues on Loop Conformation,” Protein Eng. (1991) 4: 773-783
`
`6
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1075 Queen et al., “A Humanized Antibody that Binds to the Interleukin
`2 Receptor,” Proc. Natl. Acad. Sci. USA (1989) 86: 10029-10033
`
`Exhibit 1076 Friend et al., “Phase I Study of an Engineered Aglycosylated
`Humanized CD3 Antibody in Renal Transplant Rejection,”
`Transplantation (1999) 68: 1632-1637
`
`Exhibit 1077 Brekke and Sandlie, “Therapeutic Antibodies for Human Diseases
`at the Dawn of the Twenty-First Century,” Nature Revs. Drug
`Discov. (2003) 2: 52-62
`
`Exhibit 1078 Cole et al., “Human IgG2 Variants of Chimeric Anti-CD3 are
`Nonmitogenic to T cells,” J. Immunol. (1997) 159: 3613-3621
`
`Exhibit 1079 Huse et al., International Publication No. WO 2001/27160
`
`Exhibit 1080 Reserved
`
`Exhibit 1081 Reserved
`
`Exhibit 1082 Reserved
`
`Exhibit 1083 Lisa Djavadi-Ohaniance et al., Antibody Engineering: A Practical
`Approach 77-117 (1st ed. 1996)
`
`Exhibit 1084 Van Regenmortal et al., “Improving the Quality of BIACORE-
`Based Affinity Measurements,” Dev. Biol. (Basel) (2003) 112: 141-
`151
`
`Exhibit 1085 GE Healthcare, Biacore Sensor Surface Handbook (2005)
`
`Exhibit 1086 Kelley, “Thermodynamics of Protein-Protein Interaction Studied by
`Using BIAcore and Single-Site Mutagenesis,” Methods (1994) 6:
`111-120
`
`Exhibit 1087 Johnstone et al., “The Effect of Temperature on the Binding
`Kinetics and Equilibrium Constants of Monoclonal Antibodies to
`Cell Surface Antigens,” Mol. Immunol. (1990) 27: 327-333
`
`7
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1088 Carter, “Potent Antibody Therapeutics by Design,” Nature Revs.
`Immunol. (2006) 6: 343-357
`
`Exhibit 1089 Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`Exhibit 1090 Petersen et al., “Inhibitory Effect of BIBN4096BS on Cephalic
`Vasodilation Induced by CGRP or Transcranial Electrical
`Stimulation in the Rat,” Br. J. Pharm. (2004) 143: 697-704
`
`Exhibit 1091 Purves et al., Neuroscience 763-773 (3rd ed. 2004)
`
`Exhibit 1092 Reserved
`
`Exhibit 1093 Reserved
`
`Exhibit 1094 Reserved
`
`Exhibit 1095 Conner et al., “Interaction of Calcitonin-Gene-Related Peptide with
`Its Receptors,” Biochemistry Society Transactions (2002) 30(4):
`451-455
`
`Exhibit 1096 Wimalawansa, “Calcitonin Gene-Related Peptide and Its
`Receptors: Molecular Genetics, Physiology, Pathophysiology, and
`Therapeutic Potentials,” Endocrine Revs. (1996) 17(5): 533-585
`
`Exhibit 1097 Williamson et al., “Intravital Microscope Studies on the Effects of
`Neurokinin Agonists and Calcitonin Gene-Related Peptide on
`Dural Vessel Diameter in the Anaesthetized Rat,” Cephalalgia
`(1997) 17: 518-524
`
`Exhibit 1098 Reserved
`
`Exhibit 1099 Reserved
`
`Exhibit 1100 Reserved
`
`Exhibit 1101 Jones et al., “Replacing the Complementarity-Determining Regions
`in a Human Antibody with Those from a Mouse,” Nature (1986)
`
`8
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`
`
`
`Exhibit
`
`321: 522-525
`
`Exhibit 1102 Reserved
`
`Exhibit 1103 Tysabri® Letter from the Food and Drug Administration (2004)
`
`Exhibit 1104 Pollack, “F.D.A. Approves a Multiple Sclerosis Drug,” New York
`Times (November 24, 2004)
`
`Exhibit 1105 Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,” Am. J.
`Gastroenterol (2003) 98: 2372-2382
`
`Exhibit 1106 Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M. (eds)
`Tumor Targeting in Cancer Therapy. Cancer Drug Discovery and
`Development. Humana Press, Totowa, NJ.
`
`Exhibit 1107 Knight et al., “Pharmacodynamic Enhancement of the Anti-Platelet
`Antibody Fab Abciximab by Site-Specific Pegylation,” Platelets
`(2004) 15: 409-418
`
`Exhibit 1108 RituxanTM (rituximab) Prescribing Information (1997)
`
`Exhibit 1109 Reff et al., “Depletion of B Cells in vivo by a Chimeric Mouse
`Human Monoclonal Antibody to CD20,” Blood (1994) 83: 435-445
`
`Exhibit 1110 Tsurushita et al., “Design of Humanized Antibodies: From anti-Tac
`to Zenapax,” Methods (2005) 36: 69-83
`
`Exhibit 1111 Simulect® (basiliximab) Prescribing Information (1998)
`
`Exhibit 1112 Synagis® (palivizumab) EMA Scientific Discussion (2004)
`
`Exhibit 1113 Wu et al., “Ultra-Potent Antibodies Against Respiratory Syncytial
`Virus: Effects of Binding Kinetics and Binding Valence on Viral
`Neutralization,” J. Mol. Biol. (2005) 350: 126-144
`
`Exhibit 1114 Maini and Feldmann, “How Does Infliximab Work in Rheumatoid
`Arthritis?” Arthritis Res. (2002) 4: S22-S28
`
`9
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Exhibit
`Exhibit 1115 Herceptin® (trastuzumab) Prescribing Information (1998)
`
`Exhibit 1116 Carter et al., “Humanization of an Anti-p185HER2 Antibody for
`Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA (1992) 89:
`4285-4289
`
`Exhibit 1117 MabCampath® (alemtuzumab) EMA Scientific Discussion (2005)
`
`Exhibit 1118 ZevalinTM (ibritumomab tiuxetan) Prescribing Information (2001)
`
`Exhibit 1119 Santora et al., “Characterization of Noncovalent Complexes of
`Recombinant Human Monoclonal Antibody and Antigen Using
`Cation Exchange, Size Exclusion Chromatography, and BIAcore,”
`Anal. Biochem. (2001) 299: 119-129
`
`Exhibit 1120 Shields et al, “Inhibition of Allergic Reactions with Antibodies to
`IgE,” Int. Arch. Allergy Immunol. (1995) 107: 308-312
`
`Exhibit 1121 Cardarelli et al., “Binding to CD20 by Anti-B1 antibody or
`F(ab')(2) is Sufficient for Induction of Apoptosis in B-Cell Lines,”
`Cancer Immunol. Immunother. (2002) 51: 15-24
`
`Exhibit 1122 Werther et al., “Humanization of an Anti-lymphocyte Function-
`Associated Antigen (LFA)-l Monoclonal Antibody and
`Reengineering of the Humanized Antibody for Binding to Rhesus
`LFA-1,” J. Immunol. (1996) 157: 4986-4995.
`
`Exhibit 1123 Goldstein et al., “Biological Efficacy of a Chimeric Antibody to the
`Epidermal Growth Factor Receptor in a Human Tumor Xenograft
`Model,” Clin. Cancer. Res. (1995) 1: 1311-1318
`
`Exhibit 1124 Avastin® (bevacizumab) EMA Scientific Discussion (2005)
`
`Exhibit 1125 Ferrara et al., “Discovery and Development of Bevacizumab, an
`Anti-VEGF Antibody for Treating Cancer,” Nature Rev. Drug
`Discov. (2004) 3: 391-400
`
`Exhibit 1126 Léger et al., “Humanization of a Mouse Antibody against Human
`
`10
`
`
`
`
`
`
`Exhibit
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`Alpha-4 Integrin: A Potential Therapeutic for the Treatment of
`Multiple Sclerosis,” Hum. Antibodies (1997) 8: 3-16
`
`Exhibit 1127 Lilly’s U.S. Provisional Application No. 60/753,004
`
`Exhibit 1128 U.S. Provisional Application No. 60/711,950
`
`Exhibit 1129 Wu et al., “Stepwise in vitro Affinity Maturation of Vitaxin, an
`αvβ3-Specific Humanized mAb,” Proc. Natl. Acad. Sci. USA (1998)
`95: 6037-42
`
`Exhibit 1130 Janeway et al., Immunobiology 626-627 (5th ed. 2001)
`
`Exhibit 1131 Reserved
`
`Exhibit 1132 Reserved
`
`Exhibit 1133 Reserved
`
`Exhibit 1134 Pisegna et al., U.S. Patent Application Publication No.
`2004/0110170
`
`Exhibit 1135 Reserved
`
`Exhibit 1136 September 5, 2013 Teva’s Response to Office Action (U.S. Patent
`No. 8,597,649 prosecution history)
`
`Exhibit 1137 Reserved
`
`Exhibit 1138 Reserved
`
`Exhibit 1139 Reserved
`
`Exhibit 1140 Reserved
`
`Exhibit 1141 Reserved
`
`Exhibit 1142 Yang et al., “CDR Walking Mutagenesis for the Affinity
`Maturation of a Potent Human Anti-HIV-1 Antibody into the
`
`11
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`
`Description
`Picomolar Range,” J. Mol. Biol. (1995) 254: 392-403
`
`Exhibit 1143 Reserved
`
`Exhibit 1144 Reserved
`
`Exhibit 1145 Reserved
`
`Exhibit 1146 Reserved
`
`Exhibit 1147 Reserved
`
`Exhibit 1148 Reserved
`
`Exhibit 1149 Reserved
`
`Exhibit 1150 Reserved
`
`Exhibit 1151 Reserved
`
`Exhibit 1152 Reserved
`
`Exhibit 1153 Reserved
`
`Exhibit 1154 Reserved
`
`Exhibit 1155 Reserved
`
`Exhibit 1156 Reserved
`
`Exhibit 1157 Reserved
`
`Exhibit 1158 Reserved
`
`Exhibit 1159 Reserved
`
`Exhibit 1160 Reserved
`
`Exhibit 1161 Reserved
`
`12
`
`
`
`
`
`
`Exhibit
`Exhibit 1162 Reserved
`
`Exhibit 1163 Reserved
`
`Exhibit 1164 Reserved
`
`Exhibit 1165 Reserved
`
`Exhibit 1166 Reserved
`
`Exhibit 1167 Reserved
`
`Exhibit 1168 Reserved
`
`Exhibit 1169 Reserved
`
`Exhibit 1170 Reserved
`
`Exhibit 1171 Reserved
`
`Exhibit 1172 Reserved
`
`Exhibit 1173 Reserved
`
`Exhibit 1174 Reserved
`
`Exhibit 1175 Reserved
`
`Exhibit 1176 Reserved
`
`Exhibit 1177 Reserved
`
`Exhibit 1178 Reserved
`
`Exhibit 1179 Reserved
`
`Exhibit 1180 Reserved
`
`Exhibit 1182 Reserved
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`13
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Description
`
`
`
`
`Exhibit
`Exhibit 1183 Reserved
`
`Exhibit 1184 Reserved
`
`Exhibit 1185 Reserved
`
`Exhibit 1186 Reserved
`
`Exhibit 1187 Reserved
`
`Exhibit 1188 Reserved
`
`Exhibit 1189 Reserved
`
`Exhibit 1190 Reserved
`
`Exhibit 1191 Reserved
`
`Exhibit 1192 Reserved
`
`Exhibit 1193 Reserved
`
`Exhibit 1194 Reserved
`
`Exhibit 1195 Reserved
`
`Exhibit 1196 May 5, 2017 Application Data Sheet (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1197 June 26, 2017 Office Action (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1198 August 23, 2017 Teva’s Response to Office Action (U.S. Patent
`No. 9,890,211 prosecution history)
`
`Exhibit 1199 August 23, 2017 Terminal Disclaimers (U.S. Patent No. 9,890,211
`prosecution history)
`
`Exhibit 1200 May 26, 2017 Information Disclosure Statement (U.S. Patent No.
`
`14
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`Exhibit
`
`Description
`9,890,211 prosecution history)
`
`Exhibit 1201 August 23, 2017 Information Disclosure Statement (U.S. Patent
`No. 9,890,211 prosecution history)
`
`Exhibit 1202 October 27, 2017 Information Disclosure Statement (U.S. Patent
`No. 9,890,211 prosecution history)
`
`
`
`
`
`
`Date: August 8, 2018
`
`
`
`Respectfully submitted,
`
`
`
`By: /William B. Raich/
`William B. Raich (Reg. No. 54,386)
`Erin M. Sommers (Reg. No. 60,974)
`Pier D. DeRoo (Reg. No. 69,340)
`Yieyie Yang (Reg. No. 71,923)
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, L.L.P.
`901 New York Avenue, N.W.
`Washington, D.C. 20001-4413
`Telephone: 202-408-4000
`Facsimile: 202-408-4400
`
`Sanjay M. Jivraj (Reg. No. 61,806)
`Mark J. Stewart (Reg. No. 43,936)
`Eli Lilly and Company Lilly Corporate
`Center
`Indianapolis, IN 46285
`
`15
`
`
`
`
`
`
`
`
`
`
`
`Petitioner’s Exhibit List
`U.S. Patent No. 9,890,211
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), the undersigned certifies
`
`that on August 8, 2018 a copy of the foregoing Petitioner’s Exhibit List as of
`
`August 8, 2018 and Exhibits 1001, 1012-1013, 1019-1035, 1038-1052, 1055-
`
`1079, 1083-1091, 1095-1097, 1101, 1103-1130, 1134, 1136, 1142, 1196-1202
`
`were served by Priority Mail Express on the correspondence address of record
`
`indicated in the Patent Office’s public PAIR system for U.S. Patent No. 9,890,211:
`
`FISH & RICHARDSON P.C. (BO)
`P.O. Box 1022
`Minneapolis, MN 55440-1022
`
`A courtesy copy of the foregoing was also served by FedEx on the attorney
`
`
`
`for assignee Teva Pharmaceuticals International GmbH indicated in Patent Office’s
`
`public PAIR system for U.S. Patent No. 9,890,211:
`
`Elizabeth T. Karnas, Ph.D.
`FISH & RICHARDSON P.C.
`601 Lexington Avenue
`52nd Floor
`New York, NY 10022-4611
`
`
`Date: August 8, 2018
`
`
`
`
`
`
`
`
`
`
`
`By: /William Esper/
`William Esper
`Litigation Legal Assistant
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
